There are 2789 resources available
534P - Larotrectinib in non-CNS TRK fusion cancer patients: Outcomes by prior therapy and performance status
Presenter: Alexander Drilon
Session: ePoster Display
535P - Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase (TRK) fusion cancer
Presenter: Marcia S. Brose
Session: ePoster Display
596P - Impact of combined lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Blossom Mak
Session: ePoster Display
597P - A phase I dose-escalation study of LAE001 in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Dingwei Ye
Session: ePoster Display
598P - A phase Ib study of enzalutamide (Enza) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Jimmy Zhao
Session: ePoster Display
599P - A phase I dose-escalation study of LAE001/prednisone plus afuresertib in patients with metastatic castration-resistant prostate cancer (mCRPC) following standard of care (SOC) treatment
Presenter: Alberto Bessudo
Session: ePoster Display
600P - Final results of phase I/II trial of fractionated dose 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Scott Tagawa
Session: ePoster Display
602P - Prevalence of castration-resistant prostate cancer (CRPC) of unknown metastatic status in the real-world setting: The AfrODiTA study
Presenter: Miguel Rodrigo-Aliaga
Session: ePoster Display